uniQure N.V. (QURE) jumped $6.10, or 9.4%, to $70.74 on 2.5 million shares Tuesday. The move, on nearly 5x the stock's average volume, came on no news from the gene therapy company. The stock, which had a steep ascent from around $28 to just under $70 in the first three months of the year, looks poised to resume the uptrend, as Tuesday's move broke it out above the March double-top. Watch for $80-85 next.
Disclaimer: This site may include market analysis. All ideas, opinions, alerts and/or forecasts, expressed or implied herein, are for informational purposes only and should not be construed as a recommendation to invest, trade, and/or speculate in the markets. Any investments, trades, and/or speculations made in light of the ideas, opinions, alerts and/or forecasts, expressed or implied herein, are committed at your own risk, financial or otherwise.
Investors should consider the investment objectives and unique risk profile of Exchange Traded Funds (ETFs) carefully before investing. ETFs are subject to risks similar to those of other diversified portfolios. Leveraged and Inverse ETFs may not be suitable for all investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies.
Momentum investing usually involves a strict set of rules based on technical indicators that dictate market entry and exit points for particular securities. Momentum investors sometimes use two longer-term moving averages, one a bit shorter than the other, for trading signals. Some use 50-day and 200-day moving averages, for example. The 50-day crossing above the 200-day creates a buy signal. A 50-day crossing back below the 200-day creates a sell signal. A few momentum investors prefer to use even longer-term moving averages for signaling purposes.